Serial Number 86524164
606

Registration Progress

Application Filed
Feb 4, 2015
Under Examination
Sep 8, 2015
Approved for Publication
Jul 14, 2015
Published for Opposition
Jul 14, 2015
Registered

Re-Apply for This Trademark

This trademark is no longer active. You may be able to file a new application for the same or similar mark.
Mark:
Previous Owner: ProteoTech Inc
Classes: 005

Trademark Image

Basic Information

Serial Number
86524164
Filing Date
February 4, 2015
Published for Opposition
July 14, 2015
Abandonment Date
April 10, 2017
Drawing Code
2000

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Apr 10, 2017
Classes
005

Rights Holder

ProteoTech Inc

03
Address
12040 115th Ave NE
Kirkland, WA 98034

Ownership History

ProteoTech Inc

Original Applicant
03
Kirkland, WA

ProteoTech Inc

Owner at Publication
03
Kirkland, WA

Legal Representation

Attorney
Dana B. Robinson

USPTO Deadlines

No Upcoming Deadlines

No upcoming deadlines found for this trademark.

Application History

37 events
Date Code Type Description Documents
Apr 10, 2017 MAB6 O ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED Loading...
Apr 10, 2017 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
Sep 24, 2016 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Sep 24, 2016 NOAC E CORRECTED NOA E-MAILED Loading...
Sep 23, 2016 EX2G S SOU EXTENSION 2 GRANTED Loading...
Sep 8, 2016 EXT2 S SOU EXTENSION 2 FILED Loading...
Sep 23, 2016 DPCC D DIVISIONAL PROCESSING COMPLETE Loading...
Sep 8, 2016 DRRR I DIVISIONAL REQUEST RECEIVED Loading...
Sep 8, 2016 ERTD I TEAS REQUEST TO DIVIDE RECEIVED Loading...
Sep 8, 2016 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Aug 27, 2016 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Aug 27, 2016 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Jun 3, 2016 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jun 2, 2016 EX1G S SOU EXTENSION 1 GRANTED Loading...
Mar 8, 2016 EXT1 S SOU EXTENSION 1 FILED Loading...
May 27, 2016 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Apr 19, 2016 NREV E NOTICE OF REVIVAL - E-MAILED Loading...
Apr 19, 2016 TPEX I SOU EXTENSION RECEIVED WITH TEAS PETITION Loading...
Apr 19, 2016 PETG O PETITION TO REVIVE-GRANTED Loading...
Apr 19, 2016 PROA I TEAS PETITION TO REVIVE RECEIVED Loading...
Apr 11, 2016 MAB6 O ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED Loading...
Apr 11, 2016 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
Sep 8, 2015 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Jul 14, 2015 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Jul 14, 2015 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jun 24, 2015 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Jun 10, 2015 PREV O LAW OFFICE PUBLICATION REVIEW COMPLETED Loading...
Jun 10, 2015 ALIE A ASSIGNED TO LIE Loading...
May 20, 2015 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
May 20, 2015 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
May 20, 2015 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
May 20, 2015 GNEA F EXAMINERS AMENDMENT E-MAILED Loading...
May 20, 2015 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
May 11, 2015 DOCK D ASSIGNED TO EXAMINER Loading...
Feb 14, 2015 MDSC E NOTICE OF DESIGN SEARCH CODE E-MAILED Loading...
Feb 13, 2015 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Feb 7, 2015 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical agents affecting metabolism; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the prevention of as well as management, diagnosis and prognosis of autoimmune, inflammatory, metastatic, hematologic, oncologic, neurologic and metabolic diseases, conditions, and disorders, and diseases, conditions, and disorders associated with misfolded proteins, and diseases, conditions and disorders affecting the systemic and central nervous system.; Pharmaceutical preparations for the treatment and prevention of as well as management, diagnosis and prognosis of the following specific list of enumerated indications: autoimmune, inflammatory, metastatic, hematologic, oncologic and neurologic diseases, conditions and disorders, and diseases, conditions and disorders associated with misfolded proteins, and diseases, conditions and disorders affecting the central nervous system, and psoriasis, psoriatic arthritis, rheumatoid arthritis, dermatitis, host/graft rejections, Alzheimer's and Parkinson's-disease, insulin resistance, systemic metabolic disorders, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, dementia pugilistica /chronic traumatic encephalopathy, inclusion body myositosis, mild cognitive impairment, chronic inflammation, Familial Mediterranean Fever, plasma cell (B-cell) dyscrasias, prion diseases, dialysis related amyloidosis and carpal tunnel syndrome, senile cardiac amyloidosis, Familial Amyloidotic Polyneuropathy, medullary carcinoma of the thyroid and type II diabetes
First Use Anywhere: 0
First Use in Commerce: 0

Additional Information

Design Mark
The mark consists of a counter clockwise spiraling group of shaded and variously sized and colored dots ranging from blue in the center dot and getting progressively lighter as the dots go farther from the center, ending with several green dots.
Color Claim
The color(s) green and blue is/are claimed as a feature of the mark.

Classification

International Classes
005